Hepatology COVID-19 Registry
Week 3 Report

6 new cases added to the report since last week

<table>
<thead>
<tr>
<th>Chronic liver disease (N=9)</th>
<th>Post-liver transplantation (N=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender (%)</strong></td>
<td>Female = 4 (44.5%)</td>
</tr>
<tr>
<td></td>
<td>Male = 5 (55.5%)</td>
</tr>
<tr>
<td><strong>Median Age (yr) at time of COVID diagnosis (range)</strong></td>
<td>5 (0.25-15)</td>
</tr>
<tr>
<td><strong>Etiology of liver disease</strong></td>
<td>Biliary atresia = 4</td>
</tr>
<tr>
<td></td>
<td>Autoimmune hepatitis = 1</td>
</tr>
<tr>
<td></td>
<td>NAFLD = 2</td>
</tr>
<tr>
<td></td>
<td>Idiopathic Cholestasis = 1</td>
</tr>
<tr>
<td></td>
<td>Metabolic disorder = 1</td>
</tr>
<tr>
<td><strong>Highest level of care</strong></td>
<td></td>
</tr>
<tr>
<td>Outpatient</td>
<td>3</td>
</tr>
<tr>
<td>Hospital floor</td>
<td>5</td>
</tr>
<tr>
<td>ICU</td>
<td>1</td>
</tr>
<tr>
<td><strong>Immunosuppression at time of COVID diagnosis</strong></td>
<td>Azathioprine = 1</td>
</tr>
<tr>
<td>(*some patients were on multiple agents)</td>
<td>No Immunosuppression = 8</td>
</tr>
<tr>
<td></td>
<td>Hydroxychloroquine + Azithromycin = 2</td>
</tr>
<tr>
<td></td>
<td>IVIG =1</td>
</tr>
<tr>
<td></td>
<td>Tocilizumab and Sarilumab = 1</td>
</tr>
<tr>
<td><strong>Specific Treatment for COVID</strong></td>
<td>Hydroxychloroquine + Azithromycin = 2</td>
</tr>
<tr>
<td>(*some patients were on multiple agents)</td>
<td>IVIG =1</td>
</tr>
<tr>
<td></td>
<td>Tocilizumab and Sarilumab = 1</td>
</tr>
<tr>
<td><strong>Highest respiratory support</strong></td>
<td>Hydroxychloroquine + Azithromycin = 2</td>
</tr>
<tr>
<td>None</td>
<td>6</td>
</tr>
<tr>
<td>Nasal cannula/CPAP/BiPAP</td>
<td>1</td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>1</td>
</tr>
<tr>
<td>Pending information</td>
<td>1</td>
</tr>
<tr>
<td><strong>Final clinical outcome</strong></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>0</td>
</tr>
<tr>
<td>Recovery</td>
<td>7</td>
</tr>
<tr>
<td>Still active in clinical course</td>
<td>1</td>
</tr>
<tr>
<td>Pending information</td>
<td>1</td>
</tr>
<tr>
<td><strong>Liver related Complications</strong></td>
<td>Ascites = 3</td>
</tr>
<tr>
<td></td>
<td>Portal Hypertension Bleeding =1</td>
</tr>
<tr>
<td></td>
<td>None = 5</td>
</tr>
</tbody>
</table>
Presenting symptoms at time of diagnosis

Baseline ALT levels (CLD + Post LT group)

* Other symptoms reported: Malaise, reduced oral intake

Change done to Immunosuppressive agent (Post LT group)

Peak ALT Levels (CLD + Post LT Group)

* Stopped, decreased the dose, others and No changes
Commonest agent stopped: Mycophenolate Mofetil

* Red dot denotes median, blue dots individual levels (Median ALT 37, range 19-200)

* Red dot denotes median, blue dots individual values (Median ALT 95, range 20-424)